Abstract
A patient with myelofibrosis with myeloid metaplasia displaying the V617F mutation of the JAK2 gene was given an allogeneic stem cell transplantation using a reduced-intensity conditioning regimen. The patient engrafted, and as he became a chimera, the expression of the V617F mutation of the JAK2 gene decreased progressively until its disappearance. Accordingly, the concept of "molecular remission" of the myelofibrosis with myeloid metaplasia could be entertained and added to the categories of response to treatment which have been recently described.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 400-402 |
| Number of pages | 3 |
| Journal | American journal of hematology |
| Volume | 82 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2007 |
Keywords
- Bone marrow transplantation
- JAK2 V617F mutation
- Molecular remission
- Myelofibrosis with myeloid metaplasia
ASJC Scopus subject areas
- Hematology
Fingerprint Dive into the research topics of 'Clearance of the Janus Kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia'. Together they form a unique fingerprint.
Cite this
Ruiz-Argüelles, G. J., Garcés-Eisele, J., Reyes-Núñez, V., Ruiz-Delgado, G. J., Rosillo, C., & Camoriano, J. K. (2007). Clearance of the Janus Kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. American journal of hematology, 82(5), 400-402. https://doi.org/10.1002/ajh.20832